Related references
Note: Only part of the references are listed.Active pharmacovigilance of the seasonal trivalent influenza vaccine produced by Instituto Butantan: A prospective cohort study of five target groups
Tazio Vanni et al.
PLOS ONE (2021)
Effect of Previous-Season Influenza Vaccination on Serologic Response in Children During 3 Seasons, 2013-2014 Through 2015-2016
Huong Q. McLean et al.
JOURNAL OF THE PEDIATRIC INFECTIOUS DISEASES SOCIETY (2020)
Pharmacovigilance capacity strengthening for WHO prequalification: The case of the trivalent influenza vaccine manufactured by Institute Butantan
Marcelo E. Koike et al.
VACCINE (2019)
Prospective cohort studies to evaluate the safety and immunogenicity of the 2013, 2014, and 2015 seasonal influenza vaccines produced by Instituto Butantan
Gabriella Mondini et al.
REVISTA DO INSTITUTO DE MEDICINA TROPICAL DE SAO PAULO (2018)
A trivalent, inactivated influenza vaccine (Vaxigrip®): summary of almost 50 years of experience and more than 1.8 billion doses distributed in over 120 countries
Margaret Haugh et al.
EXPERT REVIEW OF VACCINES (2017)
Immunogenicity and safety of the Southern Hemisphere 2015 formulation of Vaxigrip®
Mathilde Latreille-Barbier et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2017)
Public health impact and economic benefits of quadrivalent influenza vaccine in Latin America
Aurelien Jamotte et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2017)
Effects of Repeated Annual Inactivated Influenza Vaccination among Healthcare Personnel on Serum Hemagglutinin Inhibition Antibody Response to A/Perth/16/2009 (H3N2)-like virus during 2010-11
Mark G. Thompson et al.
VACCINE (2016)
Persistence of Antibodies to Influenza Hemagglutinin and Neuraminidase Following One or Two Years of Influenza Vaccination
Joshua G. Petrie et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
Influenza vaccines in low and middle income countries A systematic review of economic evaluations
Joerdis J. Ott et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2013)
A randomized controlled study to evaluate the immunogenicity of a trivalent inactivated seasonal influenza vaccine at two dosages in children 6 to 35 month of age
Noris Pavia-Ruz et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2013)
Immunologic non-inferiority of a newly licensed inactivated trivalent influenza vaccine versus an established vaccine A randomized study in US adults
James D. Campbell et al.
HUMAN VACCINES (2011)
A phase I randomized, double-blind, controlled trial of 2009 influenza A(H1N1) inactivated monovalent vaccines with different adjuvant systems
Alexander R. Precioso et al.
VACCINE (2011)
Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons
Lisa A. Jackson et al.
BMC INFECTIOUS DISEASES (2010)
Share Paper
